Intrahepatic Cholangiocarcinoma
Conditions
Keywords
PD-1 Antibody, Capecitabine, Intrahepatic Cholangiocarcinoma, Adjuvant therapy
Brief summary
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center,non-randomized ,single arm exploratory study . This clinical study is an investigator-initiated clinical trial(IIT) .The objective of this study is to evaluate the efficacy and safety of therapy with anti-PD-1 antibody SHR-1210 plus Capecitabine in patients with Intrahepatic Cholangiocarcinoma After Surgery.
Interventions
DRUGPD-1 blocking antibody SHR-1210
PD1 antibody SHR-1210 D1 200 mg every three weeks; Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
DRUGCapecitabine
Capecitabine 2500mg / m2/ d, 2 times/d for 2 weeks, followed by 1 week of stopping ,Three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis (requires imaging to determine tumor recurrence or metastasis)
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* age:18-75 years, male or femal; * Intrahepatic Cholangiocarcinoma confirmed by histopathology, R0 resection was classified as Stage IB, Stage II, Stage IIIA, Stage IIIB, or Stage IA with histolgoic grade G3 according to AJCC TNM (8th edition, 2017); * No extrahepatic metastases; * preoperative assessment of Child-Pugh A，ECOG Performance Status 0-1; * Subjects with chronic HBV infection must have HBV-DNA \<500 IU / ml; * Functional indicators of vital organs meet the following requirements: Neutrophils ≥1.5\*109/L; platelets≥50\*109/L; hemoglobin≥90g/l; Alanine aminotransferase （ALT） and Aspartate aminotransferase （AST） ≤ 2.5 times ULN,total bilirubin≤1.5 ULN; International standardized ratio (INR) ≤2.3ULN,creatinine ≤1.5 ULN; * No tumor recurrence or metastasis was observed.
Exclusion criteria
* Pathological diagnosis of hepatocellular carcinoma, mixed liver cancer, hilar bile duct cancer; * No anti-tumor treatment for Intrahepatic Cholangiocarcinoma, including chemotherapy and topical treatment, before surgery; * Known history of hypersensitivity to macromolecular protein preparation or any components of the SHR- 1210 formulation; * Tumors are not completely removed, or postoperative pathology suggests non-Intrahepatic Cholangiocarcinoma or other malignant components; * Subjects with any active autoimmune disease or history of autoimmune disease; * Uncontrolled clinically significant heart disease, including but not limited to the following: (1) \> NYHA II congestive heart failure; (2) unstable angina, (3) myocardial infarction within the past 1 year; (4) clinically significant supraventricular arrhythmia or ventricular arrhythmia requirement for treatment or intervention; * Active infection or an unexplained fever \> 38.5°C during screening or before the first scheduled day of dosing (subjects with tumor fever may be enrolled at the discretion of the investigator); * Received a live vaccine within 4 weeks of the first dose of study medication; * .Pregnancy or breast feeding; * Decision of unsuitableness by principal investigator or physician-in- charge.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| recurrence-free survival | 24 months | From the date of enrollment to the date of diagnosis of tumor recurrence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 24 months | From the date of enrollment to the date of death |
| the potential side effects | 24 months | — |
Countries
China
Outcome results
None listed